Research output per year
Research output per year
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Profiles
-
Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results
Cortes, J. E., Sasaki, K., Kim, D. W., Hughes, T. P., Etienne, G., Mauro, M. J., Hochhaus, A., Lang, F., Heinrich, M. C., Breccia, M., Deininger, M., Goh, Y. T., Janssen, J. J. W. M., Talpaz, M., de Soria, V. G. G., le Coutre, P., DeAngelo, D. J., Damon, A., Cacciatore, S., Polydoros, F., & 2 others, 2024, (Accepted/In press) In: Leukemia.Research output: Contribution to journal › Article › peer-review
Open Access1 Citation (Scopus) -
Clinical outcomes of chronic myeloid leukaemia patients taking asciminib through a Managed Access Programme (MAP) in Australia
Chee, L., Lee, N., Grigg, A., Chen, M., Schwarer, A., Szer, J., Ratnasingam, S., Raj, S., Lukito, P., Yeung, D., Hughes, T. & Shanmuganathan, N., 2024, (Accepted/In press) In: Internal Medicine Journal.Research output: Contribution to journal › Article › peer-review
Open Access -
IDH-mutant myeloid neoplasms are associated with seronegative rheumatoid arthritis and innate immune activation
Hong, L. E., Wechalekar, M. D., Kutyna, M., Small, A., Lim, K., Thompson-Peach, C., Li, J. J., Chhetri, R., Scott, H. S., Brown, A., Hahn, C. N., Yeung, D. T., Sajid, S., Robinson, N., Thomas, R., Branford, S., D'Andrea, R. J., Samaraweera, S. E., Patnaik, M., Proudman, S., & 4 others, 2024, (Accepted/In press) In: Blood.Research output: Contribution to journal › Article › peer-review
Open Access1 Citation (Scopus)
Prizes
Activities
-
Chronic Myeloid Leukamia (CML) Research Group (Organisational unit)
Yazad Irani (Chair)
31 Mar 2021 → …Activity: Membership › Membership of committee
-
Mitochondrial DNA mutations are associated with response to imatinib in chronic myeloid leukaemia patients. Pagani IS, Kok CH, Dang P, Lim K, Saunders VA, Hughes M, Kutyna MM, Hiwase DK, Yeung DT, Thomas D, Hughes TP, Ross DM.
Ilaria Pagani (Speaker)
2021 → …Activity: Invited talks and oral presentations › Oral conference presentations and other invited talks
-
MEK inhibitors as a targeted therapy approach to overcome resistance in Ph+ ALL cell line with PTPN11 mutations. Poudel G, Asari K, Yeung DT, White DL, Hughes TP, Pagani IS.
Ilaria Pagani (Speaker)
2021Activity: Invited talks and oral presentations › Oral conference presentations and other invited talks